Total Funding
40
55
Total FundingPost-IPO Equity raised
Growth Score
-6 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
196541
TYME is an emerging biotech developing cancer therapeutics intended to be broadly effective across tumor types with low toxicity profiles.
Acquired by 
Syros Pharmaceuticals
Steven Hoffman: Founder & CEO
About the Company
TYME Inc. is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s
innate metabolic requirements to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s immune system.
